Placebo matching with Saxagliptin
Sponsors
AstraZeneca
Conditions
Diabetes Mellitus, Type 2Type 2 Diabetes
Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
CompletedNCT01434186
Start: 2012-05-31End: 2016-04-30Updated: 2017-04-18
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
CompletedNCT01606007
Start: 2012-07-31End: 2014-01-31Updated: 2017-05-15
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes
CompletedNCT01619059
Start: 2012-06-30End: 2015-01-31Updated: 2016-04-22
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
CompletedNCT02284893
Start: 2014-09-09End: 2016-09-20Updated: 2018-06-01